

Adverse Effects of Vaccines: Evidence and Causality

ISBN 978-0-309-21435-3

896 pages 6 x 9 HARDBACK (2012) Kathleen Stratton, Andrew Ford, Erin Rusch, and Ellen Wright Clayton, Editors; Committee to Review Adverse Effects of Vaccines; Institute of Medicine





Visit the National Academies Press online and register for...

Instant access to free PDF downloads of titles from the

NATIONAL ACADEMY OF SCIENCES

NATIONAL ACADEMY OF ENGINEERING

INSTITUTE OF MEDICINE

NATIONAL RESEARCH COUNCIL

10% off print titles

Custom notification of new releases in your field of interest

Special offers and discounts

Distribution, posting, or copying of this PDF is strictly prohibited without written permission of the National Academies Press. Unless otherwise indicated, all materials in this PDF are copyrighted by the National Academy of Sciences. Request reprint permission for this book



Adverse Effects of Vaccines

Evidence and Causality

Committee to Review Adverse Effects of Vaccines

Board on Population Health and Public Health Practice

Kathleen Stratton, Andrew Ford, Erin Rusch, and Ellen Wright Clayton,

Editors

INSTITUTE OF MEDICINE
OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS Washington, D.C. www.nap.edu

THE NATIONAL ACADEMIES PRESS 500 Fifth Street, N.W. Washington, DC 20001

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance.

This study was supported by Contract No. HHSH230200446009I, Task Order 13 between the National Academy of Sciences and the Health Resources and Services Administration of the U.S. Department of Health and Human Services. The Centers for Disease Control and Prevention and the National Vaccine Program Office also provided support through that contract. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of the organizations or agencies that provided support for this project.

Library of Congress Cataloging-in-Publication Data

Institute of Medicine (U.S.). Committee to Review Adverse Effects of Vaccines.

Adverse effects of vaccines: evidence and causality / Committee to Review Adverse Effects of Vaccines, Board on Population Health and Public Health Practice; Kathleen Stratton ... [et al.], editors.

p.; cm.

Includes bibliographical references and index.

ISBN 978-0-309-21435-3 (hardcover) — ISBN 978-0-309-21436-0 (PDF)

I. Stratton, Kathleen R. II. Title.

[DNLM; 1. Vaccines—adverse effects. 2. Bacterial Infections—prevention & control. 3.

Causality. 4. Virus Diseases-prevention & control. QW 805]

615.3'72-dc23

2012007052

Additional copies of this report are available from the National Academies Press, 500 Fifth Street, N.W., Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; Internet, http://www.nap.edu.

For more information about the Institute of Medicine, visit the IOM home page at: www.iom.edu.

Copyright 2012 by the National Academy of Sciences. All rights reserved.


Printed in the United States of America

The serpent has been a symbol of long life, healing, and knowledge among almost all cultures and religions since the beginning of recorded history. The serpent adopted as a logotype by the Institute of Medicine is a relief carving from ancient Greece, now held by the Staatliche Museen in Berlin.

Suggested citation: IOM (Institute of Medicine). 2012. Adverse effects of vaccines: Evidence and causality. Washington, DC: The National Academies Press.

"Knowing is not enough; we must apply. Willing is not enough; we must do."

—Goethe



INSTITUTE OF MEDICINE OF THE NATIONAL ACADEMIES

Advising the Nation. Improving Health.

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Ralph J. Cicerone is president of the National Academy of Sciences.

The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. Charles M. Vest is president of the National Academy of Engineering.

The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Harvey V. Fineberg is president of the Institute of Medicine.

The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy's purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicinc. Dr. Ralph J. Cicerone and Dr. Charles M. Vest are chair and vice chair, respectively, of the National Research Council.

www.national-academies.org

COMMITTEE TO REVIEW ADVERSE EFFECTS OF VACCINES

- Ellen Wright Clayton (Chair), Craig-Weaver Professor of Pediatrics; Director, Center for Biomedical Ethics and Society; Professor of Law; Vanderbilt University
- Inmaculada B. Aban, Associate Professor, Department of Biostatistics, University of Alabama, Birmingham
- Douglas J. Barrett, Professor, Departments of Pediatrics, Molecular Genetics & Microbiology, Pathology, Immunology, & Laboratory Medicine, University of Florida College of Medicine
- Martina Bebin, Associate Professor of Neurology and Pediatrics, University of Alabama at Birmingham
- Kirsten Bibbins-Domingo, Associate Professor and Attending Physician, University of California, San Francisco
- Graham A. Colditz, Associate Director for Prevention and Control, Alvin J. Siteman Cancer Center, and Niess-Gain Professor in the School of Medicine, Department of Surgery, Washington University School of Medicine
- Martha Constantine-Paton, Investigator, McGovern Institute for Brain Research; Professor of Biology, Department of Biology, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology
- Deborah J. del Junco, Senior Epidemiologist and Associate Professor of Biostatistics, Epidemiology, and Research Design, University of Texas Health Science Center at Houston
- Betty A. Diamond, Head, Center for Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, North Shore-LIJ Health System
- S. Claiborne Johnston, Associate Vice Chancellor of Research; Director, Clinical and Translational Science, Institute Professor of Neurology and Epidemiology; Director, Neurovascular Disease and Stroke Center; University of California, San Francisco
- Anthony L. Komaroff, Steven P. Simcox, Patrick A. Clifford, and James H. Higby Professor of Medicine; Senior Physician, Brigham and Women's Hospital; Harvard Medical School
- B. Paige Lawrence, Associate Professor of Environmental Medicine; Associate Professor of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry
- M. Louise Markert, Associate Professor of Pediatrics and Immunology, Division of Pediatric Allergy and Immunology, Department of Pediatrics, Duke University Medical Center

¹Committee member resigned August 2010.

- Ruby H. N. Nguyen,² Assistant Professor, Division of Epidemiology and Community Health, University of Minnesota School of Public Health
- Marc C. Patterson, Chair, Division of Child and Adolescent Neurology; Professor of Neurology, Pediatrics, and Medical Genetics; Director, Child Neurology Training Program, Mayo Clinic
- Hugh A. Sampson, Professor of Pediatrics and Immunology; Dean for Translational Biomedical Sciences; Director of the Jaffe Food Allergy Institute, Mount Sinai School of Medicine
- Pauline A. Thomas, Associate Professor, Department of Preventive Medicine and Community Health, New Jersey Medical School; and Associate Professor, School of Public Health, University of Medicine and Dentistry of New Jersey
- Leslie P. Weiner, Richard Angus Grant, Sr. Chair in Neurology; Professor of Neurology and Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California

Study Staff

Kathleen Stratton, Study Director
Andrew Ford, Program Officer
Erin Rusch, Research Associate
Trevonne Walford, Research Assistant (from August 2009)
William McLeod, Senior Research Librarian
Hope Hare, Administrative Assistant
Amy Pryzbocki, Financial Associate
Rose Marie Martinez, Director, Board on Population Health and Public
Health Practice

²Committee member resigned March 2010.

Reviewers

This report has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise, in accordance with procedures approved by the National Research Council's Report Review Committee. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published report as sound as possible and to ensure that the report meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the deliberative process. We wish to thank the following individuals for their review of this report:

Steven Black, Cincinnati Children's Hospital
Patricia K. Crumrine, University of Pittsburgh School of Medicine
Anne A. Gershon, Columbia University College of Physicians &
Surgeons

Maric R. Griffin, Vanderbilt University Medical Center Neal Halsey, Johns Hopkins Bloomberg School of Public Health Diane Harper, University of Missouri-Kansas City School of Medicine Gerald T. Nepom, University of Washington Richard Platt, Harvard Medical School Stanley A. Plotkin, University of Pennsylvania Sam Shekar, Northrop Grumman Donald Silberberg, University of Pennsylvania Medical Center

Contents

SUMMARY	
Charge to the Committee, 2	
Assessing the Weight of Evidence, 10	
Causality Assessment, 14	
Causality Conclusions, 17	
Susceptibility, 24	
Concluding Comment, 24	
References, 24	
1 INTRODUCTION	27
	21
Charge to the Committee, 30 Committee Process, 36	
A CONTROL OF THE CONT	
Outline of the Report, 36	
References, 36	
2 APPROACH	39
Literature Searching, 40	
Weight of Evidence, 42	
Causality Assessment, 48	
Special Considerations, 54	
References, 54	

xiii

xiv		CONTENTS
3	EVALUATING BIOLOGICAL MECHANISMS OF ADVERSE EVENTS Latency Between Antigen Exposure and Peak Adaptive Immune Response, 57 Immune-Mediated Mechanisms, 59 Viral Activity, 76 Injection-Related Adverse Events, 78 Coagulation and Hypercoagulable States, 81 Increased Susceptibility, 82 Alterations in Brain Development, 85 Contribution of Animal Models, 89 References, 91	57
4	MEASLES, MUMPS, AND RUBELLA VACCINE Introduction, 103 Measles Inclusion Body Encephalitis, 108 Encephalitis and Encephalopathy, 111 Febrile Seizures, 119 Afebrile Seizures, 133 Meningitis, 137 Ataxia, 143 Autism, 145 Acute Disseminated Encephalomyelitis, 153 Transverse Myelitis, 154 Optic Neuritis, 156 Neuromyelitis Optica, 158 Multiple Sclerosis Onset in Adults, 159 Multiple Sclerosis Onset in Children, 164 Guillain-Barré Syndrome, 165 Chronic Inflammatory Disseminated Polyneuropathy, 166 Opsoclonus Myoclonus Syndrome, 167 Brachial Neuritis, 168 Anaphylaxis, 169 Transient Arthralgia in Women, 174 Transient Arthralgia in Children, 182 Chronic Arthralgia in Women, 190	103
	Chronic Arthritis in Women, 195 Chronic Arthropathy in Children, 199 Arthropathy in Men, 201 Type 1 Diabetes, 204 Hepatitis, 211 Chronic Fatigue Syndrome, 212 Fibromyalgia, 213	

xvCONTENTS Hearing Loss, 214 Concluding Section, 217 References, 222 VARICELLA VIRUS VACCINE 239 Introduction, 239 Disseminated Oka VZV Without Other Organ Involvement, 242 Disseminated Oka VZV with Other Organ Involvement, 249 Vaccine-Strain Viral Reactivation Without Other Organ Involvement, 256 Vaccine-Strain Viral Reactivation with Other Organ Involvement, 261 Encephalopathy, 267 Seizures, 268 Cerebellar Ataxia, 269 Acute Disseminated Encephalomyelitis, 271 Transverse Myelitis, 272 Guillain-Barré Syndrome, 273 Small Fiber Neuropathy, 274 Anaphylaxis, 275 Onset or Exacerbation of Arthropathy, 278 Stroke, 279 Thrombocytopenia, 281 Concluding Section, 282 References, 285 INFLUENZA VACCINE 293 Introduction, 293 Encephalitis and Encephalopathy, 296 Seizures, 301 Acute Disseminated Encephalomyelitis, 308 Transverse Myelitis, 309 Optic Neuritis, 310 Neuromyelitis Optica, 314 Multiple Sclerosis Onset in Adults, 314 Multiple Sclerosis Relapse in Adults, 318 Guillain-Barré Syndrome, 321 Chronic Inflammatory Disseminated Polyneuropathy, 334 Bell's Palsy, 335 Brachial Neuritis, 340 Small Fiber Neuropathy, 340

Anaphylaxis, 341

CONTENTS xviInactivated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease Episodes in Children and Adults, 345 Live Attenuated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease Episodes in Children Younger Than 5 Years of Age, 356 Live Attenuated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease Episodes in Persons 5 Years of Age or Older, 366 Onset or Exacerbation of Systemic Lupus Erythematosus, 373 Onset or Exacerbation of Vasculitis, 379 Polyarteritis Nodosa, 383 Onset or Exacerbation of Arthropathy, 384 Stroke, 386 Myocardial Infarction, 387 Fibromyalgia, 389 All-Cause Mortality, 390 Oculorespiratory Syndrome, 391 Concluding Section, 401 References, 405 421 HEPATITIS A VACCINE Introduction, 421 Acute Disseminated Encephalomyelitis, 423 Transverse Myelitis, 424 Multiple Sclerosis, 425 Guillain-Barré Syndrome, 426 Chronic Inflammatory Disseminated Polyneuropathy, 427 Bell's Palsy, 427 Anaphylaxis, 428 Autoimmune Hepatitis, 429 Concluding Section, 430 References, 432 435 HEPATITIS B VACCINE Introduction, 435 Encephalitis and Encephalopathy, 437 Seizures, 438 Acute Disseminated Encephalomyelitis, 440 Transverse Myelitis, 442 Optic Neuritis, 443 Neuromyelitis Optica, 446 Multiple Sclerosis Onset in Adults, 447 Multiple Sclerosis Onset in Children, 454

xvii CONTENTS Multiple Sclerosis Relapse in Adults, 455 Multiple Sclerosis Relapse in Children, 457 First Demyelinating Event in Adults, 458 First Demyelinating Event in Children, 464 Guillain-Barré Syndrome, 465 Chronic Inflammatory Disseminated Polyneuropathy, 466 Brachial Neuritis, 467 Anaphylaxis, 468 Erythema Nodosum, 469 Onset or Exacerbation of Systemic Lupus Erythematosus, 471 Onset or Exacerbation of Vasculitis, 473 Onset or Exacerbation of Polyarteritis Nodosa, 477 Onset or Exacerbation of Psoriatic Arthritis, 479 Onset or Exacerbation of Reactive Arthritis, 480 Onset or Exacerbation of Rheumatoid Arthritis, 482 Onset or Exacerbation of Juvenile Idiopathic Arthritis, 485 Type 1 Diabetes, 488 Fibromyalgia, 490 Concluding Section, 490 References, 494 505 HUMAN PAPILLOMAVIRUS VACCINE Introduction, 505 Acute Disseminated Encephalomyelitis, 507 Transverse Myelitis, 508 Neuromyelitis Optica, 509 Multiple Sclerosis, 510 Guillain-Barré Syndrome, 511 Chronic Inflammatory Disseminated Polyneuropathy, 512 Brachial Neuritis, 512 Amyotrophic Lateral Sclerosis, 513 Anaphylaxis, 515 Transient Arthralgia, 516 Pancreatitis, 517 Thromboembolic Events, 519 Hypercoagulable States, 520 Concluding Section, 520 References, 522 10 DIPHTHERIA TOXOID-, TETANUS TOXOID-, AND 525 ACELLULAR PERTUSSIS-CONTAINING VACCINES Introduction, 525

Encephalitis and Encephalopathy, 534

xviii

	Infantile Spasms, 537 Seizures, 539 Ataxia, 544 Autism, 545 Acute Disseminated Encephalomyelitis, 546 Transverse Myelitis, 547 Optic Neuritis, 549 Multiple Sclerosis Onset in Adults, 550 Multiple Sclerosis Relapse in Adults, 554 Multiple Sclerosis Relapse in Children, 555 Guillain-Barré Syndrome, 557 Chronic Inflammatory Disseminated Polyneuropathy, 558 Opsoclonus Myoclonus Syndrome, 560 Bell's Palsy, 561 Anaphylaxis, 563 Chronic Urticaria, 565 Serum Sickness, 566 Arthropathy, 567 Type 1 Diabetes, 571 Myocarditis, 579 Fibromyalgia, 581 Sudden Infant Death Syndrome, 581 Immune Thrombocytopenic Purpura, 582 Concluding Section, 584 References, 589	
11	MENINGOCOCCAL VACCINE Introduction, 599 Encephalitis and Encephalopathy, 602 Acute Disseminated Encephalomyelitis, 603 Transverse Myelitis, 604 Multiple Sclerosis, 605 Guillain-Barré Syndrome, 606 Chronic Inflammatory Disseminated Polyneuropathy, 607 Anaphylaxis, 608 Chronic Headache, 610 Concluding Section, 610 References, 612	599
12	INJECTION-RELATED ADVERSE EVENTS Complex Regional Pain Syndrome, 615 Deltoid Bursitis, 618 Syncope, 620	615

CONTENTS